Enofelast (BI-L-239) is a potent and selective 5-lipoxygenase inhibitor. It inhibited leukotriene B4 and C4 generation. In animal models, enofelast attenuates bronchoconstriction, leukocyte infiltration, inflammation and hyperresponsiveness that characterize asthma.

Topixantrone (BBR 3576) is a hetero-analog of the anthrapyrazole class of compounds. The mechanism of action of BBR 3576 is similar to that of mitoxantrone in terms of DNA intercalation, DNA affinity, topoisomerase II interaction and formation of single-strand breaks. BBR 3576 showed curative antitumor activity at the maximum tolerated dose (MTD) with a number of long-term survivors and showed greater activity than mitoxantrone and doxorubicin in preclinical studies. BBR 3576 retained a high level of activity across a wide range of doses. In human xenograft studies, equivalent antitumor activity was observed when compared with doxorubicin and mitoxantrone. The compound showed reduced cardiotoxicity when repeatedly administered in rodent models. Topixantrone has a manageable toxicity profile on a 4-week schedule.

Clonixeril is a glyceryl ester of a nonsteroid anti-inflammatory drug clonixin, developed by Scherico Ltd in the 1970s. Oral administration of clonixeril delays the onset of castor oil-induced diarrhoea in rats.

Tanogitran (also called as BIBT986) is a dual inhibitor of thrombin/factor Xa. Tanogitran participated in a clinical trial in endotoxin-induced coagulation, where was shown that tanogitran was a potent anticoagulant. In addition, the drug was studied in phase II clinical trial for the treatment of septic shock; however, information about the further development of this drug is not available.